1 – 12 of 12
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
A Relationship between the Structures and Neurotoxic Effects of Aβ Oligomers Stabilized by Different Metal Ions
(
- Contribution to journal › Article
- 2023
-
Mark
Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of α-Synuclein Aggregates
(
- Contribution to journal › Article
- 2021
-
Mark
Proliferation of Tau 304-380 Fragment Aggregates through Autocatalytic Secondary Nucleation
(
- Contribution to journal › Article
-
Mark
Surface-Catalyzed Secondary Nucleation Dominates the Generation of Toxic IAPP Aggregates
(
- Contribution to journal › Article
-
Mark
A dopamine metabolite stabilizes neurotoxic amyloid-β oligomers
(
- Contribution to journal › Article
- 2020
-
Mark
Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter
(
- Contribution to journal › Article
- 2019
-
Mark
Trodusquemine enhances Aβ42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes
(
- Contribution to journal › Article
- 2018
-
Mark
SAR by kinetics for drug discovery in protein misfolding diseases
2018) In Proceedings of the National Academy of Sciences of the United States of America 115(41). p.10245-10250(
- Contribution to journal › Article
-
Mark
Cholesterol catalyses Aβ42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes
(
- Contribution to journal › Article
- 2017
-
Mark
Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates
2017) In Proceedings of the National Academy of Sciences of the United States of America 114(30). p.8005-8010(
- Contribution to journal › Article
-
Mark
Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease
2017) In Proceedings of the National Academy of Sciences of the United States of America 114(2). p.200-208(
- Contribution to journal › Article
- 2016
-
Mark
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.
(
- Contribution to journal › Article